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Abstract Glycogen synthase kinase-3L (GSK-3L) has been
described as a proline-directed kinase which phosphorylates tau
protein at several sites that are elevated in Alzheimer paired
helical filaments. However, it has been claimed that GSK-3L can
also phosphorylate the non-proline-directed KXGS motifs in the
presence of heparin, including Ser262 in the repeat domain of
tau, which could induce the detachment of tau from microtubules.
We have analyzed the activity of recombinant GSK-3L and of
GSK-3L preparations purified from tissue, using two-dimensional
phosphopeptide mapping, immunoblotting with phosphorylation-
sensitive antibodies, and phosphopeptide sequencing. The most
prominent phosphorylation sites on tau are Ser396 and Ser404
(PHF-1 epitope), Ser46 and Thr50 in the first insert, followed by
a less efficient phosphorylation of other Alzheimer phosphoepi-
topes (antibodies AT-8, AT-270, etc). We also show that the non-
proline-directed activity at KXGS motifs is not due to GSK-3L
itself, but to kinase contaminations in common GSK-3L
preparations from tissues which are activated upon addition of
heparin.
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1. Introduction
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine
protein kinase, originally named after its ability to phospho-
rylate and inactivate glycogen synthase in the pathway of
insulin-dependent glycogen synthesis. It is now known to be
involved in a variety of signalling pathways a¡ecting cell fate
determination, oncogenesis, and metabolism (for reviews, see
[35,53]), notably the wingless signalling pathway in which
GSK-3L phosphorylates L-catenin, causing its ubiquitination
and degradation. The kinase exists as two main isoforms,
GSK-3K, the dominant form in most tissues, and GSK-3L,
which is enriched in brain. Both forms occur in the cytoplasm
and nucleus, but partial (10%) mitochondrial localization
seems to be restricted to GSK-3L [20]. The phosphorylation
of glycogen synthase by GSK-3L represents a well-known
paradigm of sequential phosphorylation where a priming
phosphorylation by CK-II is followed by four further phos-
phorylation events by GSK-3L in the direction towards the
N-terminus, each separated by three intervening residues
(motif SP2XXXSP1 [36]). This principle of a priming phos-
phorylation is also realized in other GSK-3 substrates, e.g.
phosphatase-1 G-subunit, inhibitor-2 of PP-1, transcription
factor CREB and eIF2B [53]. In addition, GSK-3 phosphoryl-
ates proline-directed motifs in a variety of proteins without
requiring a priming phosphorylation, e.g. transcription factors
c-Jun, c-myc, L-myc, and the microtubule-associated protein
tau [9,18,28,55]. Because of this preference, GSK-3L is often
described as a proline-directed kinase, although there are
exceptions to the rule.
GSK-3L has recently received attention in Alzheimer’s dis-
ease (AD) research for several reasons: the Wnt signalling
pathway is implicated in interaction and processing of prese-
nilin 1 (PS1) whose missense mutations are linked to familiar
AD. PS1 interacts with L-catenin, GSK-3L, and tau protein,
and these interactions are modi¢ed in the familial AD muta-
tions of PS1 [48,58,60]. AL-induced neurotoxicity is thought
to be mediated by GSK-3L [47]. GSK-3L can phosphorylate
tau protein (the subunit of Alzheimer neuro¢brillary tangles)
in a fashion reminiscent of AD tau [18,28]. The epitope of
antibody AT-100 that is highly speci¢c for Alzheimer tau is
generated by the sequential action of GSK-3L and PKA [59].
Finally, the phosphorylation of mitochondrial pyruvate dehy-
drogenase by GSK-3L could contribute to the downregulation
of acetylcholine synthesis in AD [20].
The activity of GSK-3L is regulated antagonistically by ser-
ine and tyrosine phosphorylation. Phosphorylation of Tyr216
in the regulatory loop of GSK-3L is essential for activity; in
cells, this tyrosine is constitutively phosphorylated, probably
by autophosphorylation, and thus GSK-3L can be regarded as
a dual-speci¢city kinase [32,52,57]. GSK-3L can be inhibited
by phosphorylation of Ser9 [45]. The regulatory inhibition can
be achieved by di¡erent upstream kinases and reversed by PP-
2a. It has been observed in three signal transduction path-
ways: EGF signalling through the MAP kinase pathway, in-
sulin signalling through the PI3 kinase pathway and wingless
signalling mediated by a PKC-like protein kinase [10,53].
In the case of tau protein, the enhanced phosphorylation at
Ser-Pro or Thr-Pro is a striking feature in AD brains. A
number of phosphorylation-dependent antibodies against
AD-tau exist whose epitopes require a single or two closely
spaced Ser/Thr-Pro motifs; examples are PHF-1, AT-8, AT-
270, AT-180, SMI-31, TP-3 [15] (Fig. 1). These antibodies are
used to diagnose the stage of AD and other tauopathies, and
the direct analysis of phosphorylation sites in tau from AD
brains indeed shows that many sites are in Ser/Thr-Pro motifs
[31]. This has directed attention to the kinases responsible for
this type of phosphorylation, i.e. the proline-directed kinases.
They include enzymes such as MAP kinase and its relatives
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(ERK, JNK, p38 stress-activated kinase [11,16]), cell cycle
kinases such as cdc2 or its neuronal relative cdk5 [1,33,50],
or GSK-3L [18,19,23,28,30,38,42,56]. The activity of such kin-
ases towards tau was studied in various cell models after
transfection of tau and/or the kinases and monitoring phos-
phorylation with the diagnostic antibodies. These experiments
showed that GSK-3L is particularly interesting since it phos-
phorylates tau well in a cellular context [26,44,8].
The functional analysis of tau phosphorylation is still a
matter of debate. A common assumption holds that phos-
phorylation of tau decreases its a⁄nity for microtubules and
thereby makes microtubules more dynamic, up to the point of
their breakdown in Alzheimer’s degenerating neurons. How-
ever, in this regard the e¡ect of phosphorylated Ser/Thr-Pro
motifs is relatively weak [2,49]. It is greatly surpassed by
phosphorylation at other non-Pro-directed motifs, such as
Ser262 located in the ¢rst KXGS motifs of the repeat domain
[2,12], or Ser214 in the £anking domain upstream of the re-
peats [6,22]. These sites are phosphorylated by non-proline-
directed kinases such as PKA (mostly at Ser214) and MARK
(Ser262 and other KXGS motifs) [12,25,37,54,59]. Cell models
with inducible phosphorylation at Ser262 by MARK can lead
to the breakdown of the microtubule network and cell degen-
eration [13]. This is reminiscent of the situation in degenerat-
ing neurons in AD where microtubules are disrupted, tau
shows elevated phosphorylation and is no longer competent
to bind to microtubules [5,31]. In the light of the strong e¡ect
of phospho-Ser262 on the tau-microtubule interaction it was
interesting that GSK-3L was claimed to be competent to phos-
phorylate this site, even though it is not part of a Ser-Pro
motif [29,42]. Conceptually this could provide a basis for
the inhibitory e¡ects of GSK-3L on the microtubule cyto-
skeleton; on the other hand, a direct role of Ser/Thr-Pro
motifs was deduced from mutagenesis experiments [19,51],
although this, too, remains a matter of debate [54].
In order to resolve the discrepancies in the literature we
have investigated the phosphorylation of tau by several types
of GSK-3L preparation, recombinant GSK-3L expressed in
Escherichia coli, commercial GSK-3L puri¢ed from rabbit
muscle, both in the absence and in the presence of heparin
which acts as a kinase enhancer. The results show that re-
combinant GSK-3L phosphorylates the regions £anking the
repeats and the N-terminal domain on tau, it has a strong
preference for proline-directed motifs and does not phospho-
rylate Ser262, with or without heparin. However, GSK-3L
preparations from rabbit muscle tissue phosphorylate proline-
and non-proline-directed motifs, including Ser262, especially
in the presence of heparin. This is explained by impurities in
the tissue-derived kinase which copurify through several steps
of puri¢cation (such as MARK or PKA). The proline-directed
activity of tissue-derived GSK-3L can be blocked by LiCl
which is a highly speci¢c inhibitor of GSK-3L [46], but LiCl
does not a¡ect the activity of the kinase impurities, proving
that the two kinds of activities arise from di¡erent enzymes.
2. Materials and methods
2.1. Proteins
Recombinant human tau proteins were expressed in E. coli using
variants of the pET vector and puri¢ed by making use of its heat
stability and by Mono S fast protein liquid chromatography [2].
GSK-3L was expressed in active form in E. coli following [52]; the
original human cDNA clone was generously provided by J.R. Wood-
gett [45]. GSK-3L puri¢ed from rabbit muscle was purchased from
UBI (Upstate Biotechnology, New York, USA).
2.2. Phosphorylation reactions
Phosphorylation reactions were carried out in 40 mM HEPES (pH
7.2) containing 10 WM tau protein, 5 mM MgCl2, 2 mM dithiothrei-
tol, 5 mM EGTA, 0.2 mM PMSF and 1 mM [Q-32P]ATP (100^200 Ci/
mol) in the presence or absence of 50 Wg/ml heparin. For inhibition of
GSK-3L 50 mM LiCl was added. Phosphorylation was assayed in
SDS gels [2] or on phosphocellulose paper discs (Life Technologies,
Inc.). The speci¢c activity of rGSK-3L was measured against phos-
pho-CREB peptide at 37‡C [52]. Autophosphorylation of GSK-3L
was done for 30 min at 37‡C in phosphorylation bu¡er with 1 WM
[Q-32P]ATP (2 Ci/Wmol).
2.3. Monoclonal antibodies
Antibodies AT8, AT180 and AT270 were obtained from Innoge-
netics (Ghent, Belgium); monoclonal antibody 12E8 was from Athena
Neurosciences (South San Francisco, CA, USA [39]); monoclonal
antibody PHF-1 was a gift from P. Davies (Albert Einstein College,
Bronx, NY, USA).
2.4. Immunoblots
For immunoblot analysis, the proteins were transferred to PVDF
membranes (Millipore, Eschborn, Germany). Residual membrane
binding sites were blocked with 5% non-fat dry milk in Tris-bu¡ered
saline following incubation with primary antibodies. The antibodies
Table 1
Phosphopeptides and phosphorylation sites of tau protein induced by phosphorylation with GSK-3L
Spot Remark Sequence Mass [D] Ser Thr
calc. obs. -P -P
S46/T50 a,d 24 DQGGYTT 67 4749 4730 + +
S46/T50 a,d 25 KDQGGYTT 67 4877 4864 + +
T50 b 45 ESPLQTPTEDGSEEPGSETSDAK 67 +
T69 b 68 STPTAEDVTAPLVDEGAPGK 87 +
T153 c 151 IATPR 155 +
T181 b 175 TPPSSGEPT 190 +
S199 b 195 SGYSSPGSPGTPGSR 209 +
S202/T205 d,e 195 SGYSSPGSPT 209 + +
T212 b 210 SRTPSLPTPPTR 221 1390 1388 +
T212/T217 b 210 SRTPSLPTPPTR 221 1470 1470 +
S235 b 231 TPPKSPSSAK 240 +
S396/S404 a,d 386 TDHGAET 406 2375 2377 +
S404 c,f 396 SPVVSGDTSPR 406 1182 1184 +
T403/S404 b 396 SPVVGSDGTSPR 406 + +
Remarks: (a) Doubly phosphorylated peptides as determined by MALDI. (b) Site was determined for MAPK [22]; another Ser or Thr might
be phosphorylated. (c) Sequence and phosphorylated residue were completely determined. (d) The ¢rst amino acids were determined as indi-
cated. (e) Partly phosphorylated at S198 and S199. (f) Containing a small fraction of S400.
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were detected with a peroxidase-conjugated antibody and visualized
using enhanced chemoluminescence (ECL) according to manufactur-
er’s instructions (Amersham-Buchler, Braunschweig, Germany).
2.5. Phosphopeptide mapping by thin layer electrophoresis/
chromatography
Following in vitro phosphorylation, kinase proteins were removed
by boiling of the samples in 0.5 M NaCl, 5 mM dithiothreitol and
centrifugation. Tau remains in the supernatant and was precipitated
by 15% trichloroacetic acid on ice. Cysteine residues were modi¢ed by
performic acid. The protein was digested overnight with trypsin
(Promega, sequencing grade) in the presence of 0.1 mM CaCl2, using
two additions of the enzyme in a ratio of 1:10^1:20 (w/w). Two-
dimensional phosphopeptide mapping on thin layer cellulose plates
(Macherey and Nagel, Du«ren, Germany) was performed according
to [4]. First dimension electrophoresis was carried out at pH 1.9 in
formic acid (88%)/glacial acetic acid/water (50:156:1794), second di-
mension chromatography at pH 3.5 in n-butyl alcohol/pyridine/glacial
acetic acid/water (150:100:30:120). The phosphorylation pattern was
scanned with a Bas2000 Bio-Imaging Analyzer (Fuji, Tokyo, Japan)
and analyzed with TINA 2.0 software (Raytest, Straubenhardt, Ger-
many). Determination of phosphorylation sites was done by MALDI,
sequencing and running samples together with samples of identi¢ed
phosphorylation patterns, as described previously [22] (Table 1).
3. Results
Fig. 2 illustrates the expression and puri¢cation of GSK-3L
from E. coli. After the ¢nal puri¢cation the protein has a
concentration of 100 Wg/ml and a speci¢c activity of 450
nmol/min/mg (measured against phospho-CREB peptide at
37‡C). Like other kinases, GSK-3L requires an activating
phosphorylation at a Tyr in its regulatory loop [52]. This
phosphorylation can be achieved by autophosphorylation of
the enzyme, as seen from the reaction with a phosphotyrosine
antibody (Fig. 2, lane 9). We tested the ability of this enzyme
to phosphorylate di¡erent tau constructs, including htau40
(the longest isoform in humane CNS) and constructs compris-
ing only the repeat domain where the KXGS motifs are lo-
Fig. 1. Diagram of major phosphorylation sites and epitopes of
antibodies on tau protein. The bar shows htau40, the longest tau
isoform in the human CNS (441 residues). It contains four repeats
in the C-terminal half which represent the core of the microtubule
binding domain, £anked by proline-rich basic regions. The two in-
serts near the N-terminus and repeat R2 may be absent in other iso-
forms due to alternative splicing. Construct K18 contains only the
four repeats and no Ser/Thr-Pro motifs, K12 has three repeats and
the downstream £anking region (see Fig. 3). Below the bar all 17
Ser/Thr-Pro motifs are indicated (open circles), as well as Ser214
and Ser 262 (open triangles) which have a strong in£uence on tau-
microtubule binding. The sites phosphorylated by GSK-3L are
shown above the bar (most prominent sites in bold, Ser396, Ser404,
Ser46, Ser50, Ser202, Thr205). Epitopes of phosphorylation-sensing
antibodies are indicated (AT-8, PHF-1, 12E8, AT-100).
Fig. 2. Preparation of recombinant GSK-3L. Lanes 1, 2, immuno-
blot of E. coli cell lysate with an antibody against GSK-3L before
and after induction with IPTG. Lanes 3, 4, SDS gel of cell lysate
before and after DEAE chromatography; lane 5, after phosphocel-
lulose chromatography; lane 6, after Cibacron blue chromatogra-
phy; lane 7, after Mono-S chromatography; lanes 8, 9, immuno-
blots with antibodies against GSK-3L and phosphotyrosine
(indicates activated kinase).
Fig. 3. a: Time course of incorporation of total phosphate into
htau40 or constructs K18 and K12 containing the repeat domain.
Bar diagrams of constructs are shown on top. Bottom curves: K12
(triangles) and K18 (U) are not signi¢cantly phosphorylated by
rGSK-3L in the absence or presence of heparin, indicating that the
repeat domain does not contain major phosphorylation sites. Middle
curve (circles): htau40 can be phosphorylated to about 4 Pi/mole-
cule in the absence of heparin. Top curve (squares): heparin roughly
doubles the rate of phosphate incorporation, up to 8 Pi/molecule.
b: Michaelis-Menten kinetics of phosphorylation of htau40 by
GSK-3L without and with heparin (bottom curve = circles, top cur-
ve = squares). The ATP concentration was held constant at 100 WM
and the reaction was performed for 15 min at 37‡C with 0.2 WM of
GSK-3L. Note that heparin (50 Wg/ml) does not a¡ect the Vmax
(about 3 pmol phosphate per min), but strongly reduces the KM
(from 12 WM to 0.6 WM), indicating an enhanced a⁄nity of the kin-
ase to the substrate tau.
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cated, including Ser262 in the ¢rst repeat. As seen in Fig. 3a,
rGSK-3L e⁄ciently phosphorylates htau40 up to four phos-
phates per molecule. The e⁄ciency is increased two-fold by
including heparin in the reaction mixture. However, the con-
structs of the repeat domain show almost no phosphorylation,
indicating that the non-proline-directed activity of rGSK-3L is
minimal, irrespective of heparin. In order to characterize the
nature of the heparin e¡ect we determined how the phospho-
rylation rates depended on the concentration of tau. The Mi-
chaelis-Menten plot (Fig. 3b) shows that heparin increases the
a⁄nity between enzyme and substrate (KM value drops 20-
fold) but leaves the maximal velocity unchanged, arguing
that the mechanism and speci¢city of the phosphorylation
reaction are not altered by the anionic cofactor.
The nature of the phosphorylation sites was determined by
two-dimensional phosphopeptide mapping. htau40 was phos-
phorylated to various extents by GSK-3L without or with
heparin, phosphopeptides were obtained by tryptic cleavage
and separated in two dimensions (Fig. 4). The identi¢cation of
the spots was done by phosphopeptide sequencing, mass spec-
trometry, and by reference to de¢ned phosphopeptides (for
details on tau phosphopeptides obtained in this way see
[22,59]). The most prominent phosphorylation sites observed
at early times are seen in Fig. 4a: Ser396 and Ser404 in the
£anking region behind the repeats, followed by Ser46 and
Thr50 in the ¢rst insert in the N-terminal domain, followed
by Ser202 and Thr205 in the £anking region upstream of the
repeats. At later times other sites became noticeable as well,
e.g. Thr212, Ser235, or Thr181. All the signi¢cant sites were in
Ser/Thr-Pro motifs, and most of them were located in epitopes
of phosphorylation-sensitive antibodies (see below). Speci¢-
cally, no phosphorylation was detected at Ser262 or other
KXGS motifs. Heparin increased the rate of phosphorylation,
but the phosphopeptide pattern was indistinguishable, show-
Fig. 4. Phosphopeptide maps of tau protein phosphorylated by recombinant GSK-3L in the absence or presence of heparin. Left, phosphoryla-
tion of tau with GSK-3L for 1 h and 16 h leads to incorporation of 1 and 4 mol phosphate/mol tau. Right, phosphorylation for 1 h and 16 h
in the presence of 50 Wg/ml heparin leads to 2 and 7 mol phosphate/mol tau. The phosphorylation sites which were identi¢ed by MALDI, se-
quencing and running samples together with samples of identi¢ed phosphorylation patterns [22] are marked. After 1 h incubation, tau protein
is mainly phosphorylated at Ser396/Ser404, Ser404 and Ser46/Thr50, whereas extended phosphorylation leads to more than a dozen spots (16
h). Note that phosphorylation speci¢city is not altered signi¢cantly after the addition of heparin.
Fig. 5. Time course of phosphorylation at selected sites. The highest
phosphorylation occurs in the peptide carrying both phospho-Ser396
and Ser404, followed by the doubly phosphorylated peptides S46/
T50 and S202/T205. Note the transient maximum in the singly
phosphorylated peptide S404 which is probably caused by sequential
phosphorylation (¢rst S404, then S396).
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ing that the same types of sites were phosphorylated with or
without heparin, and with the same relative e⁄ciencies. The
relative intensities of the phosphorylation reaction are con-
¢rmed by the time courses of phosphorylation at selected sites
shown in Fig. 5. The transient maximum of the singly phos-
phorylated peptide at S404 suggests a sequential phosphoryl-
ation in the N-terminal direction (¢rst S404, then S396), some-
what reminiscent of the sequential action of GSK-3L on
glycogen synthase. A similar situation holds for the pair
Thr50 (¢rst) and Ser45 (second, data not shown).
Several of the phosphorylation sites detected by phospho-
peptide mapping are located in epitopes of phosphorylation-
dependent antibodies against Alzheimer tau, and therefore
one would expect a reaction with these antibodies. This is
con¢rmed by the SDS gels and immunoblots shown in Fig.
6a. After phosphorylation by GSK-3L, the Mr of tau tends to
shift upwards, depending on the combination of phospho-
rylation sites (e.g. phospho-Ser404 induces a noticeable shift).
Antibodies AT-8, PHF-1, AT-270, AT-180 and others react
with the phosphorylated tau. We note, however, that the in-
tensity of the immunostaining does not necessarily re£ect the
degree of phosphorylation since this depends on the a⁄nity of
the antibodies. For example, the blots show the strongest
staining with AT-8 and AT-270, even though the correspond-
ing sites (Ser202/Thr205 and Thr181) are minor ones in the
phosphopeptide maps (Fig. 4c,d).
In contrast to the Ser/Thr-Pro motifs, the KXGS motifs of
the repeats are not phosphorylated by GSK-3L, as judged by
phosphopeptide mapping (Fig. 4), and this is con¢rmed by the
lack of reactivity with antibody 12E8 (sensitive to phosphoryl-
ated Ser262 and Ser356, Fig. 6b, lanes 3, 4). As a control we
phosphorylated these motifs with MARK, resulting in a clear
immunoreaction with 12E8 (Fig. 6b, lane 2). We therefore
conclude that GSK-3L does not phosphorylate Ser262 or oth-
er KXGS motifs, irrespective of whether heparin is present or
not.
There is a discrepancy between the results shown here and
some reports claiming that GSK-3L phosphorylates not only
Ser/Thr-Pro motifs but other sites as well, notably Ser262 in
the ¢rst KXGS motif [29,42]. We knew from previous expe-
rience [12] that protein kinases tend to copurify during prep-
aration from tissue, presumably because of the similarity of
the kinase catalytic domains. Since earlier results on tau phos-
phorylation by GSK-3L reported in the literature were mostly
obtained with the tissue-derived enzyme we performed the
experiments with commercial GSK-3L (UBI) prepared from
rabbit muscle. The protein concentration of this enzyme prep-
aration is so low that it cannot be demonstrated by SDS-
PAGE, but the purity can be assessed by allowing the sample
to autophosphorylate in the presence of [Q-32P]ATP. The auto-
radiography reveals a wide range of bands which may be
phosphorylated either by GSK-3L (Mr 46 kDa) or possibly
by other contaminating kinases (Fig. 7, lane 1). By contrast,
recombinant GSK-3L revealed only one pure band (Fig. 7,
lane 2). Next we phosphorylated tau with the commercial
GSK-3L prepared from muscle tissue and probed the phos-
phorylation sites with antibodies PHF-1 (for the pair of Ser-
Pro motifs Ser396/Ser404) and 12E8 (for Ser262 or Ser356 in
Fig. 6. Analysis of phosphoepitopes of tau after phosphorylation with recombinant GSK-3L for 4 h. a: Lane 1, SDS gel of marker proteins;
2, unphosphorylated control of htau40; 3, phosphorylated htau40, showing several bands shifted to higher Mr because of multiple phospho-
rylation sites. Lanes 4^7, immunoblots with antibodies AT-8, PHF-1, AT-270, AT-180 (for epitopes see Fig. 1). b: Immunoreactivity with anti-
body 12E8. Lane 1, recombinant htau40 (unphosphorylated control); 2, htau40 phosphorylated with MARK, resulting in phosphorylation at
12E8 epitope (Ser262, Ser356); 3 and 4, htau40 phosphorylated with GSK-3L without and with heparin, showing no 12E8 reaction.
Fig. 7. Purity of commercial and recombinant GSK-3L. Lane 1, Au-
tophosphorylation of ‘GSK-3L’ fraction derived from muscle tissue
and incubated with [Q-32P]ATP; lane 2, autophosphorylation of re-
combinant GSK-3L. The tissue-derived enzyme fraction contains a
wide range of impurities, the recombinant enzyme shows a single
homogeneous band.
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the KXGS motifs of repeats 1 or 4). In addition we used
heparin to enhance the activity of GSK-3L, and LiCl to in-
hibit it. Fig. 8a shows that the PHF-1 epitope becomes phos-
phorylated without heparin, it is enhanced by heparin, and
almost completely blocked by LiCl, showing that this epitope
is indeed a target of GSK-3L. By contrast, the 12E8 epitope is
not phosphorylated without heparin, phosphorylation be-
comes visible with heparin, but LiCl cannot inhibit it. This
proves that the phosphorylation is due to a contaminating
kinase whose activity requires enhancement by heparin but
cannot be blocked by LiCl. Both MARK and PKA would
qualify as the contaminating kinase because they phosphoryl-
ate the 12E8 epitope, are enhanced by heparin, and are not
sensitive to LiCl. As a consequence, it is not likely that GSK-
3L regulates microtubule stability in the cell via targeting of
Ser262 in tau.
4. Discussion
The phosphorylation of tau protein at Ser262 has been the
subject of several investigations because phosphorylation at
that site is particularly potent in dissociating tau from micro-
tubules, both in vitro and in cell models [2,13,49]. Since
Ser262 of tau shows enhanced phosphorylation in AD [31],
and since tau from AD brains has lost its microtubule-binding
capacity [5], it is possible that an upregulation of a Ser262
kinase could cause neuronal degeneration in AD, leading to
the loss of microtubules and breakdown of axonal tra⁄c.
Puri¢cation and cloning of a Ser262 kinase lead to the iden-
ti¢cation of MARK as the most potent kinase of Ser262 and
related KXGS motifs in tau [12,13]. Other kinases were re-
ported to have some activity towards Ser262 as well ; they
included PKA [12,25,37,54,59], CaMK-II [25,41], phospho-
rylase kinase [34], GSK-3K [56] and GSK-3L [29,42]. The ac-
tivity of MARK, PKA or CaMK-II might appear under-
standable in view of the similar consensus target sequences
(which include a positive charge three or four residues up-
stream of the phosphorylated serine, such as the lysine in
the KXGS motif [21]), but the activity of GSK-3L seems
counterintuitive since GSK-3L is a kinase which requires a
subsequent proline or a priming kinase activity which creates
the -S-X-X-X-Sp- motif. On the other hand, GSK-3L is par-
ticularly interesting in the context of AD research because it
phosphorylates tau e⁄ciently at Ser/Thr-Pro motifs that are
elevated in AD [18,19,23,26,28,30,40,42,59]. It is involved in
the wingless signalling pathway which may be perturbed in
AD due to mutations in the PS1 gene which are related to
familial AD [48,58,60]. Thus, GSK-3L may link di¡erent re-
action pathways that are important for the neurodegeneration
in AD. Because of this it would be interesting to know
whether GSK-3L would qualify as a Ser262 kinase capable
of detaching tau from microtubules, thus regulating microtu-
bule dynamics and intracellular transport [13,14]. We show
here that GSK-3L is not a Ser262 kinase. This would be con-
sistent with GSK-3L transfection experiments in COS or CHO
cells showing phosphorylation at Ser/Thr-Pro motifs but not
at Ser262 [19,27].
GSK-3L phosphorylates predominantly Ser/Thr-Pro motifs
in tau protein which occur in closely spaced pairs, in the order
S396/S404, S46/T50, and S202/T205, followed by others. The
¢rst and the third pair are epitopes of antibodies PHF-1 and
AT-8 which explains the reaction of these antibodies (Fig. 6a).
Note, however, that the antibody reaction does not provide
an accurate measure of the relative levels of phosphorylation.
The same is true for other antibodies directed against phos-
phorylated Ser-Pro motifs which show a clear reaction, even
though the phosphorylation at their epitopes is only a minute
fraction of the total (e.g. AT-270 or AT-180, Fig. 6a). Not
shown in this study is the reaction with AT-100, one of the
most speci¢c antibodies against AD tau. Its epitope requires
the sequential phosphorylation of Thr212 (a Thr-Pro motif)
by GSK-3L, followed by the phosphorylation of Ser214 by
PKA [59]. Phospho-Thr212 is visible in the phosphopeptide
maps (Fig. 4), but since PKA was not present the epitope of
AT-100 was not generated. Summarizing the observed sites,
we conclude that none of them quali¢es for a major in£uence
on the binding of tau to microtubules [2].
Another important conclusion is that the phosphorylation
of Ser262 by GSK-3L, reported in other studies, is an artefact
due to contaminations in kinase preparations from tissue.
This activity is not observed with recombinant GSK-3L, and
it cannot be suppressed by GSK-3L inhibitors such as LiCl.
The contaminating activity was only observed upon stimula-
tion with heparin, presumably because of the low concentra-
tion of the contaminant.
It is interesting to compare the speci¢city of GSK-3L to-
wards tau with that of the other major proline-directed kin-
ases discussed in the ¢eld, MAP kinase and cdc2 or cdk5.
Several groups have reported phosphorylation sites induced
by these kinases (reviewed in [15]), but in most cases they
used antibody reactions or mass spectrometry. This makes it
di⁄cult to determine the relative occupancies of sites because
Fig. 8. Tau phosphorylated by the tissue-derived GSK-3L fraction
and blotted with antibodies PHF-1 and 12E8. Each lane contains
250 ng of htau40. The kinase fraction can phosphorylate the PHF-1
epitope (Ser395/Ser404) without or with heparin (lanes 3, 4), but
this activity is strongly suppressed by the speci¢c GSK-3L inhibitor
LiCl (lane 5). The epitope of 12E8 is also induced by GSK-3L, but
becomes noticeable only in the presence of heparin (lane 4). How-
ever, this activity cannot be suppressed by 50 mM LiCl (lane 5),
showing that this is not due to GSK-3L but to another contaminat-
ing kinase, e.g. MARK or PKA.
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the signals are not linear (compare the strong signal with anti-
body AT-8, Fig. 6, with the low extent of phosphorylation at
Ser202/Thr205, Fig. 4a,b; or the strong signal with antibody
AT-270, Fig. 6, with almost no phosphorylation at Thr181,
Fig. 4c,d). The problem of quantitation can be largely over-
come by phosphopeptide mapping. Thus, MAP kinase phos-
phorylates most Ser/Thr-Pro sites rather e⁄ciently (Thr153,
Ser235 and Thr50 being most prominent [22]). The kinases
cdc2 or cdk5 show a strong preference for Ser235, Ser404,
and Ser202/Thr205 [22,49]. Therefore, even though GSK-3L,
MAP kinase, and cdk5 are almost exclusively proline-directed
with respect to tau, there is a clear di¡erence in their phos-
phorylation pro¢le.
The cellular e¡ects of GSK-3L on the cytoskeleton are only
partly understood at present. The kinase phosphorylates both
neuro¢lament subunits [17] and microtubules via their MAPs;
in the latter case there is a debate on whether GSK-3L reduces
the interaction of tau with microtubules and ability of micro-
tubules to form bundles in cells (see [51,54]). We found that
the phosphorylation of GSK-3L target motifs on tau are
somewhat inhibitory for process formation in transfected
Sf9 cells, but the phosphorylation of targets of PKA or
MARK has much more pronounced e¡ects on microtubule
dynamics in mitosis and cell process formation [3,13]. Finally,
one should note that tau has several distinct functions which
include not only microtubule stabilization, but also anchoring
of enzymes (e.g. PP-2a or PP-1 [24,43]) and membrane attach-
ment [7], and the regulation of intracellular transport by mo-
tor proteins [14]. It remains to be shown how these functions
are controlled by di¡erent kinases and their target sites on
tau.
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